@curator

1 year ago

Article

Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy - Leukemia

Rating: 0.0

Likes: 1

Library: 1

Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy - Leukemia

Infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have a dismal prognosis. Survival outcomes have remained static in recent decades despite treatment intensification and novel therapies are urgently required. KMT2A-rearranged infant ALL cells are characterized by an abundance of promoter hypermethylation and exhibit high BCL-2 expression, highlighting potential for therapeutic targeting.

Rate This Post

Rate The Educational Value

Rate The Ease of Understanding and Presentation

Interesting or Boring? Rate the Entertainment Value

Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy - Leukemia

Rate This Post

Related Topics

Comments

Media:

My Account:

Boostlane:

Select a Category

Topics Trending Today

Recommended Media

Boostlane Reward System

Unlocking the Power of Knowledge
for Humanity's Progress

Quick Links

Select a Locale

Unlocking the Power of Knowledge
for Humanity's Progress

Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy - Leukemia

Rate This Post

Related Topics

Comments

Media:

My Account:

Boostlane:

Select a Category

Topics Trending Today

Recommended Media

Boostlane Reward System

Unlocking the Power of Knowledge for Humanity's Progress

Quick Links

Select a Locale

Unlocking the Power of Knowledge for Humanity's Progress

Unlocking the Power of Knowledge
for Humanity's Progress

Unlocking the Power of Knowledge
for Humanity's Progress